Core Insights - Xcel Energy Inc. (XEL) is a major player in the electricity and natural gas sector, with a market capitalization of $44.9 billion [1] Performance Overview - Over the past year, XEL's stock has gained 13.2%, underperforming the S&P 500 Index, which has increased nearly 14% [2] - In 2026, XEL stock has shown a YTD increase of 3.2%, outperforming the S&P 500's marginal rise [2] - Compared to the Utilities Select Sector SPDR Fund (XLU), which gained about 11% over the past year, XEL's performance is relatively stronger on a YTD basis [3] Financial Results - For Q4, XEL reported revenue of $3.6 billion, reflecting a year-over-year increase of 14.1% [5] - The adjusted EPS for the quarter grew 18.5% year-over-year to $0.96 [5] - Analysts project an 8.9% growth in XEL's EPS for the fiscal year ending December 2025, estimating it to reach $3.81 on a diluted basis [5] - XEL has a mixed earnings surprise history, missing consensus estimates in three of the last four quarters [5] Analyst Ratings - Among 18 analysts covering XEL, the consensus rating is a "Strong Buy," with 14 "Strong Buy" ratings, one "Moderate Buy," and three "Holds" [6] - The analyst sentiment has improved compared to three months ago, with 13 analysts now suggesting a "Strong Buy" [8] - BTIG has maintained a "Buy" rating on XEL, lowering the price target to $94, indicating a potential upside of 23.4% from current levels [8] - The mean price target is $87.94, representing a 15.4% premium to XEL's current price, while the highest price target of $95 suggests an upside potential of 24.7% [8]

Core Viewpoint - Stanley Black & Decker, Inc. is a leading global manufacturer of tools and industrial products, with a market cap of $13.1 billion, known for its strong portfolio of brands like DeWalt, Stanley, and Craftsman [1] Financial Performance - Over the past year, Stanley Black & Decker's stock has decreased by 2.3%, but it has gained 13.9% year-to-date, while the S&P 500 Index has increased by 14% [2] - The company has underperformed compared to the State Street Industrial Select Sector SPDR Fund, which gained 23.6% over the same period [3] - In its fourth-quarter earnings report, the company posted revenue of $3.7 billion, a 1% year-over-year decline, but adjusted earnings per share of $1.41 exceeded analyst expectations [5] - The adjusted gross margin was reported at 33.3%, an increase of 210 basis points, with cash from operating activities at $956 million and free cash flow at $883 million [5] Future Outlook - For 2026, Stanley Black & Decker expects adjusted EPS to range from $4.90 to $5.70, indicating a year-over-year growth of approximately 42% and 13% at the midpoint, reflecting management's confidence in recovery and margin improvement [6] - Analysts project an adjusted EPS of $5.37 for the current year, representing a 15% increase year-over-year, with a strong earnings surprise history [7] - The consensus rating among 16 analysts covering the stock is a "Moderate Buy," consisting of five "Strong Buys," ten "Holds," and one "Strong Sell" [7]

Core Viewpoint - Mid-America Apartment Communities (MAA) has experienced a total return of -9% over the past year, significantly underperforming both the REIT index (VNQ) and the broader equity market [1] Group 1 - MAA's stock performance has been poor, indicating potential challenges within the company or the market environment [1]

Core Viewpoint - Nike Inc. shares are experiencing an upward trend, influenced by a generally positive market environment, despite some mixed signals in technical indicators and ongoing job cuts as part of automation efforts [1][2]. Group 1: Stock Performance - Nike shares are up 3.71% at $63.20, benefiting from broader market trends, with the Dow Jones up 0.62% and the S&P 500 down slightly by 0.40% [1][6]. - Over the past 12 months, Nike shares have decreased by 17.22%, indicating challenges faced by the stock [3]. Group 2: Job Cuts and Automation - Nike announced plans to cut 775 jobs at its U.S. distribution facilities, adding to the 1,000 corporate job cuts revealed last summer, primarily affecting warehouses in Tennessee and Mississippi [2]. Group 3: Technical Indicators - Nike is currently trading 0.5% below its 20-day simple moving average (SMA) and 3.5% below its 100-day SMA, reflecting short-term weakness [3]. - The Relative Strength Index (RSI) is at 38.94, indicating neutral territory, while the MACD is below its signal line, suggesting bearish pressure on the stock [4]. Group 4: Earnings Outlook and Analyst Sentiment - Investors are anticipating the next earnings report scheduled for March 19, 2026 [5]. - The stock carries a Buy Rating with an average price target of $79.70, with recent analyst actions including a Buy rating from BTIG with a target of $100 and a downgrade to Hold from Needham [6][7]. Group 5: Financial Estimates - EPS estimate is 30 cents, down from 54 cents year-over-year, and revenue estimate is $11.25 billion, down from $11.27 billion year-over-year [7]. - The stock has a P/E ratio of 35.6x, indicating a premium valuation compared to peers [7].

Core Insights - Avery Dennison reported revenue of $2.27 billion for Q4 2025, a year-over-year increase of 3.9% and an EPS of $2.45, up from $2.38 a year ago [1] - The revenue was slightly below the Zacks Consensus Estimate of $2.29 billion, resulting in a surprise of -0.94%, while the EPS exceeded the consensus estimate of $2.40 by +2.08% [1] Financial Performance Metrics - Net Sales for the Solutions Group were $724.2 million, compared to an estimated $753.41 million, reflecting a year-over-year increase of +1.5% [4] - Net Sales for the Materials Group were $1.55 billion, matching the analyst estimate and showing a +5.1% increase from the previous year [4] - Adjusted Operating income for the Corporate expense was reported at -$19.2 million, better than the estimated -$20.9 million [4] - Adjusted Operating income for the Solutions Group was $81.4 million, exceeding the average estimate of $76.24 million [4] - Adjusted Operating income for the Materials Group was $219.3 million, below the estimated $234.09 million [4] Stock Performance - Avery Dennison's shares have returned +2.6% over the past month, outperforming the Zacks S&P 500 composite, which saw a +0.9% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Amgen Inc. is a leading biotechnology company engaged in innovative therapies and treatments, operating in a competitive landscape with peers like Biogen and Gilead Sciences [1] Investment Activity - Atlantic Union Bankshares Corp increased its investment in Amgen by 66.3% in Q3, now holding 17,698 shares valued at approximately $5 million, reflecting strong investor confidence [2] - Legacy Investment Solutions LLC and Evelyn Partners Investment Management LLP have acquired new stakes in Amgen, valued at around $27,000 and $32,000 respectively, indicating growing interest in the company's potential [3] - Quaker Wealth Management LLC increased its position in Amgen by 200% in Q2, further demonstrating the rising interest among investors [3] - Atle Fund Management AB reduced its holdings in Amgen by 42.2% in Q3, now owning 13,806 shares valued at approximately $3.9 million, showcasing varied investment strategies [4] Stock Performance - Amgen's stock is currently trading at $343.63, with a slight decrease of $1.16 or -0.34% today, and has experienced a 52-week high of $353.25 and a low of $261.43 [5] - The company maintains a solid market capitalization of approximately $185 billion, reinforcing its status as a key player in the biotechnology sector [5][6]

Core Viewpoint - Analysts expect Malibu Boats (MBUU) to report a quarterly loss of -$0.03 per share, reflecting a year-over-year decline of 109.7%, with revenues projected at $186.35 million, down 7% from the previous year [1] Group 1: Earnings Estimates - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating a reevaluation of initial estimates by analysts [1][2] - Changes in earnings estimates are crucial for predicting investor reactions to the stock, with empirical studies showing a strong relationship between earnings estimate revisions and short-term price performance [2] Group 2: Revenue Projections - Revenue by product for Malibu is estimated at $68.70 million, indicating a decline of 7.3% from the year-ago quarter [4] - Revenue by product for Cobalt is projected to reach $51.85 million, reflecting a decrease of 7.4% from the prior-year quarter [4] - Revenue by product for Saltwater Fishing is expected to be $66.05 million, showing a year-over-year change of -5.9% [5] Group 3: Unit Volume and Sales Metrics - Unit Volume by Segment for Malibu is projected at 490, down from 525 reported in the same quarter last year [5] - Unit Volume by Segment for Cobalt is expected to be 313, compared to 380 in the same quarter of the previous year [6] - The consensus for Net Sales per Unit - Total is $169,800, an increase from $163,895 reported in the same quarter last year [6] - Total Unit Volume is estimated at 1,098, down from 1,222 in the year-ago quarter [6] - Unit Volume by Segment for Saltwater Fishing stands at 295, compared to 317 in the same quarter of the previous year [7] Group 4: Stock Performance - Shares of Malibu Boats have increased by 11.1% over the past month, outperforming the Zacks S&P 500 composite, which moved up by 1.8% [7] - With a Zacks Rank of 3 (Hold), MBUU is expected to mirror overall market performance in the near future [7]

Core Viewpoint - EOG Resources, Inc. is a leading oil and gas producer with a significant presence in major shale basins and Trinidad, valued at approximately $60.8 billion, focusing on high-return plays while facing mixed stock performance in recent periods [1][2][5]. Group 1: Company Overview - EOG Resources controls about 535,000 net acres in Eagle Ford and 160,000 in Dorado, concentrating on Wolfcamp, Bone Spring, and Leonard plays across oil, NGLs, and natural gas [1]. - The company generated $1.4 billion in free cash flow during Q3 2025, returning $545 million through dividends and repurchasing $440 million in shares, which bolstered investor confidence [6]. Group 2: Stock Performance - Over the past 52 weeks, EOG's shares declined by 13.6%, underperforming the S&P 500 Index, which increased by 14.3% [2]. - Year-to-date, EOG stock has risen by 6.8%, significantly outperforming the S&P 500's modest gain of 1.4% [2]. - Compared to the State Street Energy Select Sector SPDR ETF, which gained 13.2% over the past year, EOG stock has lagged [3]. Group 3: Earnings and Analyst Sentiment - In Q3 2025, EOG's revenue decreased by 2% year-over-year to $5.85 billion, slightly missing analyst expectations of $5.95 billion, while adjusted EPS fell by 6.2% to $2.71, surpassing the $2.43 estimate [5]. - For fiscal year 2025, analysts project a diluted EPS of $10.11, indicating a 13% year-over-year decline, but EOG has consistently exceeded earnings estimates in the past four quarters [7]. - The consensus rating among 34 analysts is "Moderate Buy," with 13 "Strong Buy" ratings, 2 "Moderate Buy" calls, 18 "Hold" recommendations, and 1 "Strong Sell" [7].

Core Viewpoint - Atle Fund Management AB increased its holdings in Gilead Sciences by 6.8% in Q3, indicating growing institutional interest in the biopharmaceutical company [2] Institutional Holdings - Norges Bank acquired a new stake in Gilead valued at approximately $2.15 billion in Q2 - Ameriprise Financial increased its stake by 397.6% in Q2, now owning 6,748,403 shares valued at $748.15 million after purchasing an additional 5,392,191 shares - Invesco Ltd. raised its position by 33.5% in Q2, now holding 13,521,228 shares worth $1.50 billion after buying 3,394,330 shares - Assenagon Asset Management increased its holdings by 164.4% in Q3, now owning 3,489,062 shares valued at $387.29 million after acquiring 2,169,266 shares - Vanguard Group lifted its stake by 1.6% in Q2, now owning 119,364,226 shares worth $13.23 billion after acquiring 1,893,401 shares - Institutional investors and hedge funds currently own 83.67% of Gilead's stock [3] Stock Performance - Gilead Sciences shares opened at $141.95, with a market cap of $176.11 billion - The stock has a price-to-earnings ratio of 22.01, a PEG ratio of 0.73, and a beta of 0.33 - The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45, and a quick ratio of 1.31 - The one-year low for the stock is $93.37, and the one-year high is $142.20 [4] Earnings Results - Gilead reported an EPS of $2.47 for the latest quarter, exceeding the consensus estimate of $2.16 by $0.31 - The company achieved a net margin of 27.88% and a return on equity of 51.86% - Quarterly revenue was $7.77 billion, surpassing the consensus estimate of $7.42 billion, and up 3.0% year-over-year - Analysts expect Gilead to post an EPS of 7.95 for the current year [5] Analyst Ratings - Leerink Partners raised their price target from $114.00 to $146.00, rating the stock as "outperform" - Rothschild & Co Redburn increased their target from $153.00 to $159.00 with a "buy" rating - Sanford C. Bernstein set a price objective of $135.00 with an "outperform" rating - Citigroup raised their target from $140.00 to $156.00 with a "buy" rating - HSBC lifted their target from $110.00 to $133.00 with a "hold" rating - The stock has a consensus rating of "Moderate Buy" with an average target price of $136.73 [6] Insider Activity - Director Kelly A. Kramer sold 2,805 shares at an average price of $127.10, totaling $356,515.50, reducing ownership by 67.69% - CFO Andrew D. Dickinson sold 3,000 shares at an average price of $124.31, totaling $372,930.00, a 1.95% decrease in ownership - Over the last 90 days, insiders sold 257,397 shares worth $33.39 million, with insiders owning 0.27% of the company's stock [8] Company Overview - Gilead Sciences, founded in 1987 and headquartered in Foster City, California, focuses on developing medicines for high unmet medical needs - The company is known for its antiviral therapies and has expanded into oncology, cell therapy, and inflammatory diseases [9][10]

International Business Machines Corporation (NYSE:IBM) is one of the stocks that Jim Cramer shared takes on, along with navigating market shortages. Cramer noted that the company reported a “magnificent number,” as he stated: Beyond the Mag Seven, let me throw in IBM. They reported a magnificent number. Oh my God, Mag Eight? I don’t know. Software revenues up 14, very strong full-year forecast, inexpensive stock flying in after-hours trading. You know, I think IBM’s incredibly well run by Arvind Krishna a ...